Showing 1031-1040 of 9358 results for "".
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the Valeant board until the upc…
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved topical treatment for SK. Aclaris also plans to s…
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://practicaldermatology.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2458280/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa State of the Industry Report, administered by MarketData Enterprises and sponsored by Modern Aesthetics® magazine. The report—the only up-to-date resource of its kind focusing specifically on medical spas in…
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of moderate…
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggressors and free radicals. “With the launch of our…
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the National Institute of Allergy and …
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only US Food and Drug Administration-approved prescription cream with a .05% strength emollient …
- Medical Spa State of the Industry Statistical Study Now Openhttps://practicaldermatology.com/news/medical-spa-state-of-the-industry-statistical-study-now-open/2458301/During the past five years, the medical spa industry has grown and evolved to a point where it has become one of the most exciting and lucrative new industries in the country. Because of this, it is now more important than ever that the industry have its own credible state of the industry report. I…
- Congratulations: American Skin Association Announces 2017 Research Scholar Awards and Research Grantshttps://practicaldermatology.com/news/congratulations-american-skin-association-announces-2017-research-scholar-awards-and-research-grants/2458307/And the winners are … The American Skin Association (ASA) research scholar awards and research grants are: ASA Carson Research Scholar Award in Psoriasis Cory L. Simpson, MD, PhD University of Pennsylvania Role of Autophagy in Psoriasis Pathogenesis ASA Milstein Research Scholar Awards in Melan…
- Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directorshttps://practicaldermatology.com/news/specialty-pharma-industry-vet-charles-gregory-vontz-joins-biopharmx-board-of-directors/2458311/Charles "Greg" Vontz is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17. Vontz's appointment expands the board to four directors, three of whom are independent. Vontz most recently served as president and CEO of Topica Pharmaceuticals,…